Objective: To compare the effectiveness and safety between bivalirudin and heparin with
tirofiban in patients with acute myocardial infarction by percutaneous coronary intervention …

Background Previous randomised trials of bivalirudin versus heparin in patients with ST-
segment elevation myocardial infarction (STEMI) undergoing primary percutaneous …

Aims To evaluate the effectiveness and safety of bivalirudin as used in routine care.
Bivalirudin has been studied as an alternative to heparin plus glycoprotein IIb/IIIa inhibitor …

Objectives: The purpose of this study was to describe temporal trends and determine the
comparative effectiveness of bivalirudin versus unfractionated heparin (UFH) during …

Background Optimal adjunctive therapy in ST-segment elevation myocardial infarction
(STEMI) patients treated with primary PCI (PPCI) remains a matter of debate. Our aim was to …

Background—The use of bivalirudin versus unfractionated heparin monotherapy in patients
without ST-segment–elevation myocardial infarction is not well defined. Methods and …

Background: Although the current practice guidelines recommend using both heparin and
bivalirudin for percutaneous coronary interventions (PCI), the research data are ambiguous …

Aims The HORIZONS trial reported a survival advantage for bivalirudin over heparin-with-
glycoprotein inhibitors (GPIs) in primary PCI for ST elevation myocardial infarction. This …

Bivalirudin is a member of the direct thrombin inhibitor drug class and has been investigated
as an alternative to unfractionated heparin for the treatment of patients with acute coronary …

Background—Patients treated with bivalirudin in randomized clinical trials of percutaneous
coronary intervention generally have less bleeding but more acute stent thrombosis (ST) …